We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Erik Musiek MD, PhD

Erik S. Musiek MD, PhD

Associate Professor of Neurology, Washington University, St. Louis, Missouri; Co-Director, Center on Biological Rhythms and Sleep (COBRAS)

Dr. Musiek is an Associate Professor of Neurology at Washington University School of Medicine in St. Louis and Co-Director of the Center on Biological Rhythms and Sleep (COBRAS). His lab focuses on how the circadian rhythms regulate inflammation in the brain and impact neurodegenerative disease, including Alzheimer’s Disease. He is also a clinical investigator at the Knight Alzheimer’s Disease Research Center, and is a practicing neurologist with a specialty in memory disorders and dementia. He is the recipient of the Kopolow Award for Aging Research and is a member of the American Society for Clinical Investigation. He has published more than 60 peer-reviewed papers, and serves on multiple NIH study sections and national advisory committees. He completed MD/PhD training at Vanderbilt University in 2007, neurology residency at University of Pennsylvania in 2011, and a postdoctoral fellowship in dementia at Washington University in 2013.


Dr. Musiek has research funding from the NIH and from Eisai Pharmaceuticals. Neither Dr. Musiek nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company.

Recent Contributions to PracticeUpdate:

  1. Donanemab Shows Promise in Early Alzheimer Disease